- Home
- GENI vs PVLA Comparison
GENI vs PVLA Comparison
Compare GENI & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENI | PVLA |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GENI | PVLA |
|---|---|---|
| Price | $6.59 | $151.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 15 |
| Target Price | $12.75 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 4.4M | 162.8K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 52.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,810,000.00 |
| Revenue This Year | $24.00 | N/A |
| Revenue Next Year | $20.12 | $104,350.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.28 |
| 52 Week Low | $3.83 | $54.28 |
| 52 Week High | $13.69 | $161.38 |
Technical Indicators
Market Signals| Indicator | GENI | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 52.13 |
| Support Level | $6.55 | $135.68 |
| Resistance Level | $6.95 | $160.07 |
| Average True Range (ATR) | 0.39 | 6.11 |
| MACD | -0.14 | -0.38 |
| Stochastic Oscillator | 6.67 | 56.85 |
Price Performance
Historical ComparisonAbout GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas: Sports Technology and Services; Betting Technology, Content, and Services; and Media Technology, Content, and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content, and Services division. Geographically, the company derives a majority of its revenue from America.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.